Company

Recce Pharmaceuticals Ltd

ASX:RCE

Recce Pharmaceuticals Ltd (ASX:RCE) is developing a new class of synthetic anti-infectives designed to address the urgent global health threat of antibiotic-resistant superbugs.

169 stories · page 4 of 9

Pharma & Biotech

Recce Pharmaceuticals reports positive data from Phase 1/2 UTI/urosepsis rapid infusion clinical trial of RECCE® 327

By Proactive 28/06/2024

Pharma & Biotech

Recce Pharmaceuticals gets ethics green light for RECCE® 327 Gel clinical trials across topical bacterial skin infections

By Proactive 24/06/2024

Pharma & Biotech

Recce Pharmaceuticals secures new $2.6 million R&D rebate for anti-infective platform

By Proactive 18/06/2024

Pharma & Biotech

Recce Pharmaceuticals lands WHO Antibacterial Products in Clinical Development listing for RECCE® 327

By Proactive 18/06/2024

Pharma & Biotech

Recce Pharmaceuticals completes cohort dosing in Phase 1/2 UTI/Urosepsis trial

By Proactive 11/06/2024

Pharma & Biotech

Recce Pharmaceuticals doses first participants in next cohort Phase I/II UTI/Urosepsis rapid infusion clinical trial

By Proactive 15/05/2024

Pharma & Biotech

Recce Pharmaceuticals makes breakthrough in lung infection treatment with nebulised RECCE® 327

By Proactive 09/05/2024

Pharma & Biotech

Recce Pharmaceuticals granted China patent for RECCE® Anti-Infectives

By Proactive 07/05/2024

Pharma & Biotech

Recce Pharmaceuticals R327 approved for increase to 4,000mg IV over a fast infusion of 30 minutes

By Proactive 26/04/2024

Pharma & Biotech

Recce Pharmaceuticals hits milestone with 5,000 doses a week of RECCE® 327 manufactured to exacting GMP standard

By Proactive 16/04/2024

Pharma & Biotech

Recce Pharmaceuticals selected to participate in UK Government Innovation Agency’s AMR Mission 2024

By Proactive 11/04/2024

Pharma & Biotech

Recce Pharmaceuticals advances clinical pipeline on multiple fronts with strong US backing

By Proactive 08/04/2024

Pharma & Biotech

Recce Pharmaceuticals granted Israeli patent for anti-infective treatments

By Proactive 03/04/2024

Pharma & Biotech

Recce Pharmaceuticals gaining financial leverage and progressing clinical trials, says Edison Investment Research

By Proactive 28/03/2024

Pharma & Biotech

Recce Pharmaceuticals secures Canadian trademark and R&D incentive for RECCE® synthetic anti-infectives

By Proactive 21/03/2024

Pharma & Biotech

Recce Pharmaceuticals completes dosing of latest cohort in phase 1/2 UTI/urosepsis rapid infusion clinical trial

By Proactive 15/03/2024

Pharma & Biotech

Recce Pharmaceuticals dosing next cohort in phase I/II UTI/urosepsis rapid infusion clinical trial

By Proactive 12/03/2024

Pharma & Biotech

Recce Pharmaceuticals receives $11.7M R&D advance to accelerate clinical programs

By Proactive 08/03/2024

Pharma & Biotech

Recce Pharmaceuticals gets higher valuation from Edison Investment Research

By Proactive 27/02/2024

Pharma & Biotech

Recce Pharmaceuticals continues Murdoch Children’s Research Institute partnership targeting anti-microbial resistance

By Proactive 27/02/2024